이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors

2026년 11월 12일 업데이트: Janssen Research & Development, LLC

A Phase 1 Trial of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors

The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose ([putative] recommended phase 2 dose [pRP2D] regimen[s]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

200

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion criteria:

- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specific tumor type. Participants who actively decline available standard of care therapies are eligible upon documentation of their refusal.

i. Participants with NSCLC must not have known actionable driver alteration for which a targeted therapy is available.

ii. Demonstrated radiographic progression on most recent tumor assessment imaging

  • Participants entering the study must have >=1 measurable lesion as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 that has not been previously irradiated
  • Body weight >=35 kilogram (kg) and body mass index (BMI) >=18 kilogram per square meter (kg/m^2)
  • Eastern cooperative oncology group (ECOG) performance status of 0 or 1
  • Must provide informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the protocol and in the informed consent form (ICF)

Exclusion criteria:

  • Active central nervous system (CNS) involvement with the exception of brain metastases that are clinically stable and asymptomatic for greater than (>)2 weeks off treatment and who are off or receiving low-dose corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
  • Any other malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study treatment, except for squamous and basal cell carcinoma of the skin, non-muscle invasive bladder cancer, or any malignancy considered cured or has minimal risk of recurrence within 1 year of first dose of study treatment
  • Had major surgery within 14 days prior to first dose of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the trial
  • External beam radiation therapy to soft tissue lesions within 14 days prior to start of study treatment
  • History of solid organ or allogeneic hematopoietic stem cell transplant (HSCT)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: JNJ-99220732 (Part 1 and Part 2)

Participants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first.

JNJ-99220732 will be administered intravenously.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants with Adverse Events (AE) by Severity
기간: Up to 3 years 2 months

An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event.

Up to 3 years 2 months
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
기간: Up to 21 days

A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities.

Up to 21 days

2차 결과 측정

결과 측정
측정값 설명
기간
Serum Concentration Time Profile of JNJ-99220732
기간: Up to 3 years 2 months

Serum concentrations of JNJ-99220732 over time will be reported.

Up to 3 years 2 months
Maximum Observed Concentration (Cmax) of JNJ-99220732
기간: Up to 3 years 2 months

Cmax of JNJ-99220732 will be reported.

Up to 3 years 2 months
Trough Concentration (Ctrough) of JNJ-99220732
기간: Up to 3 years 2 months

Ctrough of JNJ-99220732 will be reported.

Up to 3 years 2 months
Time to Maximum Concentration (Tmax) of JNJ-99220732
기간: Up to 3 years 2 months

Tmax of JNJ-99220732 will be reported.

Up to 3 years 2 months
Area Under the Concentration-Time Curve from Time Zero to Last Measured Time Point (AUC 0-tau) of JNJ-99220732
기간: Up to 3 years 2 months

AUC0-tau of JNJ-99220732 will be reported.

Up to 3 years 2 months
Accumulation Ratio of JNJ-99220732
기간: Up to 3 years 2 months

Accumulation ratio of JNJ-99220732 will be reported.

Up to 3 years 2 months
Number of Participants with Anti-Drug Antibodies Against JNJ-99220732
기간: Up to 3 years 2 months

Number of participants with anti-drug antibodies against JNJ-99220732 will be reported.

Up to 3 years 2 months
Objective Response Rate
기간: Up to 3 years 2 months

Objective Response Rate (ORR) is defined as percentage of participants with best objective response of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria.

Up to 3 years 2 months
Disease Control Rate (DCR)
기간: Up to 3 years 2 months

DCR is defined as the percentage of participants who achieve a confirmed best overall response of CR, PR, or stable disease (SD) based on RECIST version 1.1.

Up to 3 years 2 months
Radiographic Progression-Free Survival (rPFS)
기간: Up to 3 years 2 months

Radiographic PFS was defined as the time (in months) interval from first dose to the first date of radiographic progression or death. Radiographic progression included progression by bone scan, defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to RECIST v.1.1 criteria).

Up to 3 years 2 months
Duration of Response (DOR)
기간: Up to 3 years 2 months

DOR is defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurs first (according to RECIST v.1.1 criteria).

Up to 3 years 2 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Janssen Research & Development LLC Clinical Trial, Janssen Research & Development, LLC

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2029년 1월 5일

연구 완료 (추정된)

2030년 1월 16일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 99220732STM1001
  • 2026-527759-24-00 (레지스트리 식별자: EUCT number)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

예

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .